INVA
BULLISH
$23.76
Live
Innoviva, Inc. · NASDAQ
Target $33.2
(+39.7%)
$16.52
52W Range
$25.15
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$1.77B
P/E
7.2
ROE
29.1%
Profit margin
65.9%
Debt/Equity
0.28
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
75%
Innoviva exhibits a stark divergence between operational health trends and valuation; while the Piotroski F-Score of 3/9 indicates weak financial health trends, the company is fundamentally undervalued with a current price of $23.76 sitting well below both the Graham Number ($34.16) and the Intrinsic Value ($97.35). The company boasts exceptional profitability with a 65.92% profit margin and a PEG ratio of 0.35, suggesting massive growth potential relative to its current multiple. Despite a heavily bearish technical trend (10/100), the extreme liquidity (Current Ratio 14.64) and low debt/equity (0.28) mitigate immediate solvency risks. The bullish thesis is driven by deep value and explosive earnings growth, though the low F-Score warrants caution regarding operational efficiency.
Key Strengths
Exceptional profitability with 65.92% profit margins
Deep value valuation (P/E 7.20, PEG 0.35)
Extreme short-term liquidity with a Current Ratio of 14.64
Explosive YoY earnings growth of 590.40%
Low leverage with a Debt/Equity ratio of 0.28
Key Risks
Weak operational health trends as indicated by Piotroski F-Score (3/9)
Strongly bearish technical momentum (10/100)
High volatility in quarterly earnings surprises
Lack of recent insider buying activity
Potential concentration risk inherent in biotechnology sector
AI Fair Value Estimate
Based on comprehensive analysis
$48.5
+104.1% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
52
Moderate
95
85
50
30
0
AI Verdict
Deep Value Play
Key drivers: Extreme valuation discount, High margins, Poor operational trend scores
Confidence
80%
Value
95/100
Ref P/E, PEG, Graham Number
Positives
- P/E of 7.20 is significantly below sector average
- PEG of 0.35 indicates severe undervaluation
- Price is below Graham Number
Watchpoints
No urgent risks highlighted.
Future
85/100
Ref Growth rates
Positives
- Revenue growth of 24.80%
- Massive EPS growth trajectory
Watchpoints
- Forward P/E is higher than trailing, suggesting a slight cooling of expectations
Past
50/100
Ref Historical trends
Positives
- Strong 5Y price appreciation (+103.6%)
Watchpoints
- Inconsistent earnings track record with several large misses
Health
30/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Very low Debt/Equity
- High Current Ratio
Watchpoints
- Piotroski F-Score of 3/9 indicates deteriorating fundamentals
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend payout
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$23.76
Analyst Target
$33.2
Upside/Downside
+39.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for INVA and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
INVA
Innoviva, Inc.
Primary
|
+103.6% | +101.2% | +39.0% | +37.0% | +6.0% | +3.4% |
|
ESTA
Establishment Labs Holdings Inc.
Peer
|
-10.1% | -12.1% | +127.1% | +54.6% | -10.2% | +5.6% |
|
AZTA
Azenta, Inc.
Peer
|
-50.6% | -29.6% | -26.9% | +16.3% | +16.1% | +0.1% |
|
ANAB
AnaptysBio, Inc.
Peer
|
+227.2% | +183.1% | +284.9% | +177.0% | +17.3% | +17.0% |
|
GRAL
GRAIL, Inc.
Peer
|
+234.0% | +234.0% | +100.6% | -31.0% | -1.5% | -17.0% |
INV
Innoviva, Inc.
Primary
5Y
+103.6%
3Y
+101.2%
1Y
+39.0%
6M
+37.0%
1M
+6.0%
1W
+3.4%
EST
Establishment Labs Holdings Inc.
Peer
5Y
-10.1%
3Y
-12.1%
1Y
+127.1%
6M
+54.6%
1M
-10.2%
1W
+5.6%
AZT
Azenta, Inc.
Peer
5Y
-50.6%
3Y
-29.6%
1Y
-26.9%
6M
+16.3%
1M
+16.1%
1W
+0.1%
ANA
AnaptysBio, Inc.
Peer
5Y
+227.2%
3Y
+183.1%
1Y
+284.9%
6M
+177.0%
1M
+17.3%
1W
+17.0%
GRA
GRAIL, Inc.
Peer
5Y
+234.0%
3Y
+234.0%
1Y
+100.6%
6M
-31.0%
1M
-1.5%
1W
-17.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
7.2
Forward P/E
10.75
PEG Ratio
0.35
P/B Ratio
1.51
P/S Ratio
4.31
EV/Revenue
3.71
EV/EBITDA
7.82
Market Cap
$1.77B
Profitability
Profit margins and return metrics
Profit Margin
65.92%
Operating Margin
34.66%
Gross Margin
74.94%
ROE
29.09%
ROA
7.18%
Growth
Revenue and earnings growth rates
Revenue Growth
+24.8%
Earnings Growth
+590.4%
Q/Q Revenue Growth
+24.84%
Q/Q Earnings Growth
+707.4%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.28
Low debt
Current Ratio
14.64
Strong
Quick Ratio
13.28
Excellent
Cash/Share
$7.65
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
88.9%
Op. Margin
34.0%
Net Margin
143.2%
Total Assets
$1.6B
Liabilities
$0.5B
Equity
$1.2B
Debt/Equity
0.39x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-02-25
$1.94
+234.5% surprise
2025-11-05
$0.38
-0.1% surprise
2025-08-06
$0.77
+54.0% surprise
Healthcare Sector Comparison
Comparing INVA against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
P/E Ratio
7.2
This Stock
vs
88.64
Sector Avg
-91.9%
(Discount)
Return on Equity (ROE)
29.09%
This Stock
vs
-46.09%
Sector Avg
-163.1%
(Below Avg)
Profit Margin
65.92%
This Stock
vs
-19.58%
Sector Avg
-436.6%
(Weaker)
Debt to Equity
0.28
This Stock
vs
4.1
Sector Avg
-93.1%
(Less Debt)
Revenue Growth
24.8%
This Stock
vs
88.16%
Sector Avg
-71.9%
(Slower)
Current Ratio
14.64
This Stock
vs
3.58
Sector Avg
+309.1%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
INVA
Innoviva, Inc.
|
BULLISH | $1.77B | 7.2 | 29.1% | 65.9% | $23.76 | |
|
ESTA
Establishment Labs Holdings Inc.
|
BEARISH | $1.82B | - | -133.3% | -24.2% | $62.01 | Compare |
|
AZTA
Azenta, Inc.
|
NEUTRAL | $1.84B | 77.02 | 1.4% | -9.4% | $40.05 | Compare |
|
ANAB
AnaptysBio, Inc.
|
BULLISH | $1.86B | - | -24.5% | -5.6% | $64.81 | Compare |
|
GRAL
GRAIL, Inc.
|
BEARISH | $1.87B | - | -16.1% | -277.5% | $45.63 | Compare |
INVA
Innoviva, Inc.
BULLISH
Mkt Cap
$1.8B
P/E
7.2
ROE
29.1%
Price
$23.76
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-14 | BASSO STEPHEN | Chief Financial Officer | Stock Award | 604 | - |
| 2025-11-03 | RAIFELD PAVEL | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 112,296 | $1,999,996 |
| 2025-11-03 | BASSO STEPHEN | Chief Financial Officer | Stock Award | 27,609 | $499,999 |
BASSO STEPHEN
Chief Financial Officer
2025-11-14
604 shares
RAIFELD PAVEL
Beneficial Owner of more than 10% of a Class of Security
2025-11-03
112,296 shares
·
$1,999,996
BASSO STEPHEN
Chief Financial Officer
2025-11-03
27,609 shares
·
$499,999
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
5 analysts
BTIG
2026-02-26
Buy
Buy
BTIG
2026-02-17
Buy
HC Wainwright & Co.
2025-12-16
Buy
Buy
Cantor Fitzgerald
2025-11-06
Overweight
Overweight
Past News Coverage
Recent headlines mentioning INVA from our newsroom.
Newest → oldest
No matching news yet.